Peptide Decoding
New?New to peptides?Start here →
Decoding

Evuzamitide (AT-01)_Dosage, benefits & legal status

Also known as AT-01, 124I-AT-01, iodine-124 evuzamitide, I 124 evuzamitide, p5+14, APi1832, Api1832, AT-01 evuzamitide

Published November 21, 2026

Forty-five residues designed to stick to the sugar scaffolding every kind of amyloid is built on.

Find amyloid deposits on a scan45-residue amyloid-binding peptide, iodine-124 labeled (intravenous)Investigational
DoseA single tracer dose before imaging
FrequencyOnce per scan
RouteInto a vein (intravenous), as a radiolabeled imaging agent
StatusInvestigational
CycledA single dose before a scan

See how this dose compares across the library →

01

What is Evuzamitide (AT-01)?

Plain language first. The technical label stays, but it never stands alone.

Overview

A radioactive peptide dye that makes amyloid show up on a scan.

The technical version

A 45-residue polybasic pan-amyloid-reactive peptide, radioiodinated with iodine-124 for PET and CT imaging of systemic and cardiac amyloidosis; investigational, with phase 3 primary endpoints met in 2026.

What it's used for

An investigational PET imaging agent for diagnosing cardiac and systemic amyloidosis, approved nowhere.

02

How does Evuzamitide (AT-01) work?

What it does in the body, and where.

Amyloidosis is more than thirty different diseases wearing the same coat. Different proteins misfold, but they all end up as the same kind of fibril. Most imaging agents target one specific protein, which means you must already suspect which type you are looking for. This peptide was built to ignore the protein entirely.

  1. 01
    It targets the scaffolding, not the protein
    Amyloid deposits always contain heparan sulfate proteoglycans alongside the fibrils, and the sugar chains in amyloid are far more heavily sulfated, so more negatively charged, than those in healthy tissue. This peptide is polybasic, carrying a net positive charge of plus twelve, and it finds that unusually dense negative charge through multivalent electrostatic interactions.
  2. 02
    It only forms its shape on contact
    The peptide folds into an alpha helix in the presence of dense electronegative surfaces, which is what amyloid provides. Away from such a surface it stays unstructured. Binding and folding are the same event, which is part of why it discriminates amyloid from normal tissue.
  3. 03
    The name is the recipe
    It grew out of p5, a 31-residue heparin-binding peptide built on a repeating lysine-alanine-glutamine motif. Adding 14 more residues raised the charge and the amyloid affinity, giving p5 plus 14, which is 45 residues. The arithmetic in the name is literal.
  4. 04
    What it proved in the phase 3
    In REVEAL, an investigator-initiated study run from a Boston teaching hospital, the tracer met both primary endpoints. On the majority read of three independent blinded readers, sensitivity was 94 percent with a 95 percent interval of 85 to 98, and specificity 86 percent with an interval of 77 to 92. Those are diagnostic performance numbers. They say nothing about whether finding amyloid earlier changes what happens to the patient.
Pathway
THE PEPTIDE
Evuzamitide (AT-01)
ACTS ON
Amyloid fibrils and the heparan sulfate proteoglycans deposited with them
RESULT
Sensitivity 94 percent, 95 percent interval 85 to 98
RESULT
Specificity 86 percent, 95 percent interval 77 to 92

A schematic of the compound's mechanism, not a diagnostic image.

03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Cardiac amyloidosis diagnosis by PET and CT, the phase 3 indicationpeer-reviewed-human
  • Systemic amyloidosis across organs and amyloid types, the original research usepeer-reviewed-human
  • Measuring change in organ amyloid load over time, a registered phase 2 usetrial-protocol
  • SPECT imaging as a technetium-99m labeled version, a separate phase 1 programtrial-protocol

The published record

Research index

21

Papers about Evuzamitide (AT-01) · this compound only

Searched: Evuzamitide, APi1832.

Left out: AT-01 (a short code that matches unrelated text, kept for the trial search only); p5+14 (its older name, held back until the plus sign is confirmed to search correctly); p5 (the shorter parent peptide, a different molecule); p5R (a related peptide studied alongside it, a different molecule); AT-05 (the companion tracer, a different compound); REVEAL (the phase 3 trial's name, which is also an ordinary word); amyloid (the target, with one of the largest literatures in medicine); heparan sulfate (the molecule it binds in those deposits, with a large literature of its own); iodine-124 (the radioactive label, which is used on other tracers too); 99mTc-p5+14 (the version with a different label, which has the same plus sign problem).

21 papers tagged human · 7 not reviews or lab · 2 clinical trial publications

How the compound was given: 1 applied to skin · 6 injected · 1 by mouth or rectal · 15 route not stated in the abstract

Read from each paper's indexing terms and abstract, by rule. A paper that mentions a cream studied a cream, not necessarily the product being sold.

10 registered trials · 3 with posted results

Furthest stage reached: Phase 3, completed, no results posted

Compare this against the whole library →

In animals1
In the lab0
Reviews5
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

Evuzamitide (AT-01) vial rendering
Compound field notes

At a glance

Four things to know about Evuzamitide (AT-01)

01

Evidence

Investigational

02

Category

Immune support

03

Common vial

Varies

04

Half-life

Not published

04

How much, and do you cycle it?

The range, and whether you take breaks.

A single tracer dose before imaging, once per scan. A single dose before a scan Trial dose

It is an imaging agent, given once per scan. A registered phase 2 repeats the scan at intervals to measure change in organ amyloid load, which means repeat administration, but there is no course and nothing to cycle.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Not publishedNo figure

No peptide half-life has been published. For an imaging agent the governing timescales are different ones: how fast unbound tracer clears from blood and tissue so the picture is clean, and the physical half-life of the radioactive label. Dosimetry and biodistribution studies have been run for the technetium-99m version in healthy subjects and patients, which is the kind of study that answers this, but no figure from them was read at source during this review.

You can compare this against the whole library to see where it sits.

06

How is it given?

Dosing context and source notes.
No draw available

Given in hospital from a prepared product, so there is nothing to mix.

Given once, into a vein, by an imaging team, before a scan. No milligram figure for the iodine-124 version was read at source during this review, so none is printed. For scale, the companion technetium-99m version of the same peptide was given in a registered phase 1 as a single intravenous dose of up to 1 mg of peptide at about 20 millicuries, by slow push over roughly five seconds, which indicates the order of magnitude: a tracer quantity, not a therapeutic one. The calculator has nothing to draw, because a single imaging dose set by a nuclear medicine protocol is not a dose anyone adjusts.

07

How do you store it?

Before mixing, and after.

Given in a hospital or trial clinic, so the pharmacy stores it.

Evuzamitide (AT-01) goes into a vein and is prepared by hospital, clinic or trial pharmacy staff, following the product label or the trial protocol. Some products like this are ready-made solutions and others are powders mixed just before use, often with hours rather than weeks of shelf life once prepared. It is not a medicine people store at home.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.
  • Any use outside a clinical trial, because there is no approved product anywhere
  • Expecting it to do anything to amyloid, because it is a diagnostic agent and binding is the whole of its action
  • Pregnancy, as with any radiopharmaceutical, which is a question for the imaging team rather than a settled label statement

Stop and get help

These are emergencies. Seek care.
  • Any allergic or infusion reaction, meaning rash, swelling of the face or lips, or trouble breathing
  • There is nothing to stop in the usual sense, because it is given once before a scan

Common effects

Expected, and usually mild.
  • No published adverse event profile was read at source during this review.
  • Given once as a tracer dose before imaging, rather than as a course of treatment.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

What has happened recently

Investigational everywhere, approved nowhere. It holds Breakthrough Therapy designation from the United States Food and Drug Administration for positron emission tomography imaging in patients with suspected or known cardiac amyloidosis, which is a process designation and not an approval. The phase 3 REVEAL study met both primary endpoints, with topline announced 7 May 2026 and full results presented at a European cardiology congress with simultaneous journal publication in late August 2026, and the sponsor stated it planned to discuss the data and a submission with regulators. No application has been reported as filed or accepted. The originator is Attralus, a clinical-stage company working on systemic amyloidosis, and the peptide itself came out of an academic amyloidosis and cancer theranostics program. Bayer announced on 12 January 2026 that it had entered definitive agreements to acquire this tracer and a second amyloid radiotracer, AT-05, from Attralus, which kept its pan-amyloid removal therapeutics, and REVEAL itself was an investigator-initiated study run from a Boston teaching hospital rather than a company-run trial.

10

What else is like Evuzamitide (AT-01)?

Others in Immune support, side by side.

If you're weighing Evuzamitide (AT-01), it's worth reading Thymalin, Vilon, and Glutathione in the same class.

Guides for this compound

Sources

  • Trial protocol for 124I-AT-01 organ uptake repeatability, NCT05235269, read via a reproduction(2022)
    A registered trial protocol, read via a reproduction because ClinicalTrials.gov could not be opened during this review, and cited for the molecular description. It states that 124I-AT-01, also written 124I-p5+14 and iodine-124 evuzamitide, is an iodine-124 labeled 45 L-amino acid peptide suitable for PET and CT imaging, that AT-01, also designated p5+14 or APi1832, is a synthetic, all natural, 45 amino acid peptide with a molecular weight of 4763.46 daltons and a net positive charge of plus twelve shown to bind amyloid in vitro and in vivo, and that it binds many forms of amyloid through multivalent electrostatic interactions with the amyloid fibril and with heparan sulfate proteoglycans. It records prior clinical experience from study AMY1001, an open-label phase 1/2 PET and CT imaging study in 57 subjects, 50 with systemic amyloidosis, two asymptomatic carriers and five healthy volunteers.
  • Wall et al., Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis, Molecules 20(5):7657(2015)
    The peer-reviewed preclinical validation paper, read for the targeting rationale that the whole design rests on. It explains that amyloid is a matrix of protein fibrils together with heparan sulfate proteoglycans, that the glycosaminoglycans present in amyloid deposits are biochemically and electrochemically distinct from those in healthy tissue because of their high degree of sulfation, and that heparin-reactive peptides such as p5+14 exploit this to target and image amyloid specifically. It reports that radiolabeled p5+14 bound murine AA amyloid in vivo by molecular imaging.
  • Polybasic helical peptides bind human amyloid extracts and synthetic amyloid fibrils(2017)
    The paper describing the parent peptide, read to establish where the name comes from. It records that the heparin-binding peptide p5 is a 31-residue synthetic reagent containing a heptad repeat of the amino acid motif lysine-alanine-glutamine-lysine-alanine-glutamine-alanine, and that its reactivity with amyloid fibrils and heparin depends on ionic interactions with negatively charged determinants. A companion comparative study states that p5+14 has higher affinity for amyloid than p5 because of its increased electropositivity.
  • Clinical Confirmation of Pan-Amyloid Reactivity of Radioiodinated Peptide 124I-p5+14 (AT-01) in Patients with Diverse Types of Systemic Amyloidosis Demonstrated by PET/CT Imaging(2023)
    The clinical confirmation paper, read for the pan-amyloid claim in people. It reports ex vivo pan-amyloid reactivity of p5+14 by peptide histochemistry on animal and human tissue sections containing various types of amyloid, and clinical confirmation by PET and CT imaging in patients with diverse types of systemic amyloidosis, concluding that the data support the use of 124I-p5+14 for diagnosing varied types of systemic amyloidosis. It describes the peptide as a synthetic, polybasic, 45 amino acid peptide that forms an alpha helix in the presence of dense electronegative surfaces such as those abundant in amyloid.
  • Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis(2026)
    The sponsor's topline announcement, read as a company document and cited for the date and the regulatory status. Dated 7 May 2026, it states that the phase 3 REVEAL study met its primary endpoints demonstrating sensitivity and specificity of iodine-124 evuzamitide PET and CT for the diagnosis of cardiac amyloidosis based on visual scan interpretation, that the radiotracer had previously been granted Breakthrough Therapy designation for PET imaging in patients with suspected or known cardiac amyloidosis, and that the company planned to discuss the data and a submission with regulators. It also records that REVEAL was an investigator-initiated study run by a Boston teaching hospital.
  • Bayer Announces Latest Study Results of Investigational PET Radiotracer, imaging trade coverage of the REVEAL presentation(2026)
    Independent medical imaging trade coverage of the congress presentation, read at source for the actual performance figures, which the topline release does not give. It records that the phase 3 results were presented at a European cardiology congress in Munich and published simultaneously in a major medical journal, that the study met its primary endpoints for sensitivity and specificity based on visual scan interpretation from three independent readers, and that on the majority read, meaning agreement between at least two of three readers, sensitivity was 94 percent with a 95 percent confidence interval of 85 to 98 and specificity was 86 percent with a 95 percent confidence interval of 77 to 92. It also records that the tracer is one of two investigational amyloid radiotracers the company acquired from Attralus, its originator.
  • Phase I IND-enabling studies for the amyloid-imaging peptide p5+14 (Api1832), Journal of Nuclear Medicine abstract(2018)
    The originating group's IND-enabling abstract, read for the manufacturing and purity facts and for the alternate designation. It describes a synthetic 45 all-L-amino acid peptide developed to bind many of the roughly thirty diverse forms of systemic amyloidosis, gives the alternate name Api1832, records that the drug substance is about 95 percent pure by HPLC profiling, and places the work in preparation for an investigational new drug application to the United States Food and Drug Administration for a single-site phase 1 PET and CT imaging study of the iodine-124 labeled peptide.
  • Bayer, Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus, 12 January 2026(2026)
    The acquiring company's own announcement, read at source and cited for the originator and the date. Dated 12 January 2026 and titled Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus, it states that the two companies entered definitive agreements for Bayer to acquire AT-01, iodine-124 evuzamitide, and AT-05, a pan-amyloid reactive peptide labeled with technetium-99m, two investigational molecular imaging agents for the diagnosis of cardiac amyloidosis, from Attralus. It records that AT-01 is the first pan-amyloid imaging agent to hold Food and Drug Administration Breakthrough Therapy designation for cardiac amyloidosis, that it also holds orphan drug designation in both the United States and the European Union, and that Attralus would go on to focus on its pan-amyloid removal therapeutics. Attralus is quoted in the release through its president. An academic program page records that both agents were developed there before the sale.

Beyond these, 31 records are indexed for this compound. Browse the records